Department of Haematology, University College London Hospitals, London, United Kingdom.
Department of Haematology, University College London Hospitals, London, United Kingdom.
Hematol Oncol Stem Cell Ther. 2021 Jun;14(2):160-162. doi: 10.1016/j.hemonc.2020.01.001. Epub 2020 Mar 12.
High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) is the standard of care for eligible multiple myeloma (MM) patients with improved progression-free and overall survival. We reviewed the ambulatory care unit pathway for MM patients who underwent HDT/ASCT in a tertiary hospital to assess safety efficacy and outcomes. We concluded that the ambulatory care model offered for MM patients undergoing HDT/ASCT is a safe alternative pathway and highlighted further improvements.
大剂量化疗（HDT）联合自体干细胞移植（ASCT）是适合的多发性骨髓瘤（MM）患者的标准治疗方法，可以改善无进展生存期和总生存期。我们回顾了在一家三级医院接受 HDT/ASCT 的 MM 患者的门诊护理路径，以评估其安全性、疗效和结果。我们的结论是，为接受 HDT/ASCT 的 MM 患者提供的门诊护理模式是一种安全的替代途径，并强调了进一步的改进。
